Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 46
Filter
1.
Curr Drug Targets ; 25(2): 108-120, 2024.
Article in English | MEDLINE | ID: mdl-38151841

ABSTRACT

Antimicrobial resistance (AMR) to currently available antibiotics/drugs is a global threat. It is desirable to develop new drugs that work through a novel target(s) to avoid drug resistance. This review discusses the potential of the caseinolytic protease P (ClpP) peptidase complex as a novel target for finding novel antibiotics, emphasising the ClpP's structure and function. ClpP contributes to the survival of bacteria via its ability to destroy misfolded or aggregated proteins. In consequence, its inhibition may lead to microbial death. Drugs inhibiting ClpP activity are currently being tested, but no drug against this target has been approved yet. It was demonstrated that Nblocked dipeptides are essential for activating ClpP's proteolytic activity. Hence, compounds mimicking these dipeptides could act as inhibitors of the formation of an active ClpP complex. Drugs, including Bortezomib, Cisplatin, Cefmetazole, and Ixazomib, inhibit ClpP activation. However, they were not approved as drugs against the target because of their high toxicity, likely due to the presence of strong electrophiles in their warheads. The modifications of these warheads could be a good strategy to reduce the toxicity of these molecules. For instance, a boronate warhead was replaced by a chloromethyl ketone, and this new molecule was shown to exhibit selectivity for prokaryotic ClpP. A better understanding of the structure and function of the ClpP complex would benefit the search for compounds mimicking N-blocked dipeptides that would inhibit ClpP complex activity and cause bacterial death.


Subject(s)
Anti-Bacterial Agents , Bacteria , Endopeptidase Clp , Peptide Hydrolases , Humans , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/chemistry , Bacteria/metabolism , Dipeptides/metabolism , Endopeptidase Clp/chemistry , Endopeptidase Clp/metabolism , Peptide Hydrolases/metabolism
2.
J Biomol Struct Dyn ; : 1-14, 2023 Dec 18.
Article in English | MEDLINE | ID: mdl-38111165

ABSTRACT

The cytochrome bcc-aa3 supercomplex, a key component in the electron transport chain pathway involved in bacterial energy production and homeostasis, is a clinically validated target for tuberculosis (TB), leading to Telacebec (Q203). Telacebec is a potent candidate drug under Phase II clinical development for the treatment of drug-sensitive and drug-resistant TB. Recently, the cryo-electron microscopy structure of this supercomplex from Mycobacterium tuberculosis (Mtb) complexed with Q203 was resolved at 6.9 Å resolution (PDB ID: 7E1W). To understand the binding site (QP site) flexibility and Q203's stability at the QP site of the Mtb cytochrome bcc complex, we conducted molecular dynamics (MD) simulation and free energy analysis on this complex in an explicit hydrated lipid bilayer environment for 500 ns. Through this study, the persistence of a range of direct and indirect interactions was observed over the course of the simulation. The significance of the interactions with His375, Tyr161, Ala178, Ala179, Ile183, His355, Leu356, and Thr313 is underlined. Electrostatic energy was the primary source of the net binding free energy, regardless of the important interacting residues. The overall binding free energy for Q203 was -112.84 ± 7.73 kcal/mol, of which the electrostatic and lipophilic energy contributions were -116.31 ± 1.14 and -21.32 ± 2.35 kcal/mol, respectively. Meanwhile, DFT calculations were utilized to elucidate Q203's molecular properties. Overall, this study deciphers key insights into the cytochrome bcc-aa3 supercomplex with Q203 on the ground of molecular mechanics and quantum mechanics that may facilitate structure-based drug design and optimization for the discovery of the next-generation antitubercular drug(s).Communicated by Ramaswamy H. Sarma.

3.
J Biomol Struct Dyn ; : 1-10, 2023 Oct 25.
Article in English | MEDLINE | ID: mdl-37878080

ABSTRACT

Tuberculosis is one of the most dreadful infectious diseases, afflicting global populations with anguish. With the emergence of multi-drug resistant strains of mycobacteria, the imperative for new anti-tuberculosis drugs has grown exponentially. Thus, the current study delves into evaluating the impact of Perovskia abrotanoides and its active metabolites-namely, rosmarinic acid and its derivatives-against strains of Mycobacterium tuberculosis (Mtb). Through the use of the CRI assay, the antimycobacterial potential of the high-altitude medicinal plant P. abrotanoides was gauged, while docking and molecular dynamics simulations unveiled plausible targets. Of these, the peak antimycobacterial effectiveness was observed in the P. abrotanoides ethyl acetate extract with 125 µg/mL as minimum inhibitory concentration against various strains of M. tuberculosis, encompassing H37Rv and strains resistant to multiple drugs. Following bioassay-guided fractionation and isolation, rosmarinic acid and rosmarinic acid methyl ester emerged as potent molecules against H37Rv and multidrug-resistant M. tuberculosis strains; minimum inhibitory concentration ranging from 15 to 32 µg/mL. Additionally, out of 22 targets explored, Mtb lipoamide dehydrogenase (PDB: 3II4) and Rv2623 (PDB: 3CIS) were forecasted as potential Mtb targets for rosmarinic acid and rosmarinic acid methyl ester, respectively, a supposition further affirmed by molecular simulations (100 ns). The stability of both complexes throughout the simulation was measured by protein backbone root-mean-square deviation, substantiating their roles as respective targets for antimycobacterial activities.Communicated by Ramaswamy H. Sarma.

4.
Curr Drug Targets ; 24(8): 627-647, 2023.
Article in English | MEDLINE | ID: mdl-37291783

ABSTRACT

The extensive development in the strains of resistant bacteria is a potential hazard to public health worldwide. This necessitates the development of newer agents with the antibacterial property having new mechanisms of action. Mur enzymes catalyze the steps related to the biosynthesis of peptidoglycan, which constitutes a major part of the cell wall in bacteria. Peptidoglycan increases the stiffness of the cell wall, helping it to survive in unfavorable conditions. Therefore, the inhibition of Mur enzymes may lead to novel antibacterial agents that may help in controlling or overcoming bacterial resistance. Mur enzymes are classified into MurA, MurB, MurC, MurD, MurE, and MurF. Until-date, multiple inhibitors are reported for each class of the Mur enzymes. In this review, we have summarized the development of Mur enzyme inhibitors as antibacterial agents in the last few decades.


Subject(s)
Drug Discovery , Peptidoglycan , Humans , Anti-Bacterial Agents/pharmacology , Bacteria , Enzyme Inhibitors/pharmacology , Enzyme Inhibitors/therapeutic use
5.
Life (Basel) ; 13(3)2023 Mar 05.
Article in English | MEDLINE | ID: mdl-36983855

ABSTRACT

The endocannabinoid system consists of several phytocannabinoids, cannabinoid receptors, and enzymes that aid in numerous steps necessary to manifest any pharmacological activity. It is well known that the endocannabinoid system inhibits the pathogenesis of the inflammatory and autoimmune disease rheumatoid arthritis (RA). To the best of our knowledge, no research has been done that explains the network-pharmacology-based anti-rheumatic processes by focusing on the endocannabinoid system. Therefore, the purpose of this study is to further our understanding of the signaling pathways, associated proteins, and genes underlying RA based on the abundant natural endocannabinoids. The knowledge on how the phytocannabinoids in Cannabis sativa affect the endocannabinoid system was gathered from the literature. SwissTarget prediction and BindingDB databases were used to anticipate the targets for the phytocannabinoids. The genes related to RA were retrieved from the DisGeNET and GeneCards databases. Protein-protein interactions (high confidence > 0.7) were carried out with the aid of the string web server and displayed using Cytoscape. The Kyoto Encyclopedia of Genes and Genomes (KEGG) metabolic pathway analysis was used to perform enrichment analyses on the endocannabinoid-RA common targets. ShinyGO 0.76 was used to predict the biological processes listed in the Gene Ontology (GO) classification system. The binding affinity between the ligand and the receptors was precisely understood using molecular docking, induced-fit docking, and a molecular dynamics simulation. The network pharmacology analyses predicted that processes like response to oxygen-containing compounds and peptodyl-amino acid modification are related to the potential mechanisms of treatment for RA. These biological actions are coordinated by cancer, neuroactive ligand-receptor interaction, lipids and atherosclerosis, the calcium signaling pathway, and the Rap1 signaling pathway. According to the results of molecular docking, in the context of RA, phytocannabinoids may bind to important target proteins such PIK3CA, AKT1, MAPK9, PRKCD, BRAF, IGF1R, and NOS3. This entire study predicted the phytocannabinoids' systemic biological characteristics. Future experimental research is needed, however, to confirm the results so far.

6.
J Biomol Struct Dyn ; 41(23): 13993-14002, 2023.
Article in English | MEDLINE | ID: mdl-36970872

ABSTRACT

There is currently no drug available to treat mosquito-borne dengue. The C-terminal RNA-dependent RNA polymerase (RdRp) domain in the non-structural type 5 (NS5) protein of the dengue virus (DENV) is essential for viral RNA synthesis and replication, and therefore, it is an attractive target for the anti-dengue drug development. We report herein the discovery and validation of two novel non-nucleoside classes of small molecules as DENV RdRp inhibitors. Firstly, using the refined X-ray structure of the DENV NS5 RdRp domain (PDB-ID: 4V0R), we conducted docking, binding free-energy studies, and short-scale molecular dynamics simulation to investigate the binding sites of known small molecules that led to the optimized protein-ligand complex. Subsequently, protein structure-based screening of a commercial database (∼500,000 synthetic compounds), pre-filtered for the drug-likeness, led to the top-ranked 171 molecules, which was then subjected to structural diversity analysis and clustering. This process led to six structurally distinct and best-scored compounds that were procured from the commercial vendor, and then subjected to the in vitro testing in the MTT and dengue infection assays. It revealed two unique and structurally unique compounds, KKR-D-02 and KKR-D-03, exhibiting 84 and 81% reductions, respectively, in DENV copy number in repeated assays in comparison to the virus-infected cell controls. These active compounds represent novel scaffolds for further structure-based discovery of novel candidate molecules for the intervention of dengue.Communicated by Ramaswamy H. Sarma.


Subject(s)
Dengue Virus , Dengue , Animals , Dengue Virus/chemistry , Binding Sites , Dengue/drug therapy , Virus Replication , RNA-Dependent RNA Polymerase/chemistry , Antiviral Agents/chemistry , Viral Nonstructural Proteins/chemistry
7.
Environ Sci Pollut Res Int ; 30(10): 25569-25581, 2023 Feb.
Article in English | MEDLINE | ID: mdl-35624375

ABSTRACT

This paper reports the degradation of the sulfadiazine (SDZ) drug with a hybrid advanced oxidation process (AOP) of heterogeneous α-Fe2O3/persulfate coupled with hydrodynamic cavitation. The major objectives of the study are parametric optimization of the process and elucidation of the chemical mechanism of degradation. The optimum conditions for maximum SDZ degradation of 93.07 ± 1.67% were as follows: initial SDZ concentration = 20 ppm, pH = 4, α-Fe2O3 = 181.82 mg/L, Na2S2O8 = 348.49 mg/L, H2O2 = 0.95 mL/L, inlet pressure = 0.81 MPa (8 atm), orifice plate configuration: hole dia. = 2 mm and number of holes = 4. Density functional theory (DFT) calculations revealed that the atoms of SDZ with a high Fukui index (f 0) were potentially active sites for the attack of •OH and [Formula: see text] radicals. Fukui index calculation revealed that atom 11 N has a higher value of f 0 (0.1026) for oxidation at the α-amine group of the sulfadiazine molecule. Degradation intermediates detected through LC-MS/MS analysis corroborated the results of DFT simulations. Using these results, a chemical pathway has been proposed for SDZ degradation.


Subject(s)
Hydrogen Peroxide , Water Pollutants, Chemical , Hydrogen Peroxide/chemistry , Sulfadiazine , Hydrodynamics , Chromatography, Liquid , Tandem Mass Spectrometry , Oxidation-Reduction , Water Pollutants, Chemical/analysis
8.
Chem Biol Drug Des ; 101(3): 690-695, 2023 03.
Article in English | MEDLINE | ID: mdl-36322010

ABSTRACT

Malaria continues to be a significant public health problem threatened by the emergence and spread of resistance to artemisinin-based combination therapies and marked half a million deaths in 2016. A new imidazopyridine chemotype has been envisaged through scaffold-hopping approach combined with docking studies for putative-binding interactions with Plasmodium falciparum phosphatidylinositol-4-kinase (PfPI4K) target. The docking results steered to the synthesis of compound 1 [5-(3-(methylsulfonyl)phenyl)-3-(4-(methylsulfonyl)phenyl)-3H-imidazo[4,5-b]pyridine] followed by the in vitro screening for antiplasmodial activity and ADME-PK studies. Combined with potent antimalarial activity of compound 1 (Pf3D7 IC50  = 29 nM) with meager in vitro intrinsic clearance, moderate plasma-protein binding, and acceptable permeability, compound 1 displayed sustained exposure and high oral bioavailability in mice and can thus have the potential as next generation PI4K inhibitor for in vivo studies.


Subject(s)
Antimalarials , Folic Acid Antagonists , Malaria , Mice , Animals , Antimalarials/pharmacology , Antimalarials/chemistry , Malaria/drug therapy , Plasmodium falciparum , Pyridines/chemistry
9.
Genes (Basel) ; 13(7)2022 07 15.
Article in English | MEDLINE | ID: mdl-35886037

ABSTRACT

Cervical cancer (CC) is a preventable disease using proven interventions, specifically prophylactic vaccination, pervasive disease screening, and treatment, but it is still the most frequently diagnosed cancer in women worldwide. Patients with advanced or metastatic CC have a very dismal prognosis and current therapeutic options are very limited. Therefore, understanding the mechanism of metastasis and discovering new therapeutic targets are crucial. New sequencing tools have given a full visualization of the human transcriptome's composition. Non-coding RNAs (NcRNAs) perform various functions in transcriptional, translational, and post-translational processes through their interactions with proteins, RNA, and even DNA. It has been suggested that ncRNAs act as key regulators of a variety of biological processes, with their expression being tightly controlled under physiological settings. In recent years, and notably in the past decade, significant effort has been made to examine the role of ncRNAs in a variety of human diseases, including cancer. Therefore, shedding light on the functions of ncRNA will aid in our better understanding of CC. In this review, we summarize the emerging roles of ncRNAs in progression, metastasis, therapeutics, chemo-resistance, human papillomavirus (HPV) regulation, metabolic reprogramming, diagnosis, and as a prognostic biomarker of CC. We also discussed the role of ncRNA in the tumor microenvironment and tumor immunology, including cancer stem cells (CSCs) in CC. We also address contemporary technologies such as antisense oligonucleotides, CRISPR-Cas9, and exosomes, as well as their potential applications in targeting ncRNAs to manage CC.


Subject(s)
Exosomes , Uterine Cervical Neoplasms , Exosomes/genetics , Exosomes/metabolism , Female , Humans , Neoplastic Stem Cells/metabolism , Prognosis , RNA, Untranslated/genetics , RNA, Untranslated/metabolism , Tumor Microenvironment , Uterine Cervical Neoplasms/genetics
10.
Mol Divers ; 26(3): 1345-1356, 2022 Jun.
Article in English | MEDLINE | ID: mdl-34110578

ABSTRACT

Tuberculosis (TB) is an infectious disease and the leading cause of death globally. The rapidly emerging cases of drug resistance among pathogenic mycobacteria have been a global threat urging the need of new drug discovery and development. However, considering the fact that the new drug discovery and development is commonly lengthy and costly processes, strategic use of the cutting-edge machine learning (ML) algorithms may be very supportive in reducing both the cost and time involved. Considering the urgency of new drugs for TB, herein, we have attempted to develop predictive ML algorithms-based models useful in the selection of novel potential small molecules for subsequent in vitro validation. For this purpose, we used the GlaxoSmithKline (GSK) TCAMS TB dataset comprising a total of 776 hits that were made publicly available to the wider scientific community through the ChEMBL Neglected Tropical Diseases (ChEMBL-NTD) database. After exploring the different ML classifiers, viz. decision trees (DT), support vector machine (SVM), random forest (RF), Bernoulli Naive Bayes (BNB), K-nearest neighbors (k-NN), and linear logistic regression (LLR), and ensemble learning models (bagging and Adaboost) for training the model using the GSK dataset, we concluded with three best models, viz. Adaboost decision tree (ABDT), RF classifier, and k-NN models that gave the top prediction results for both the training and test sets. However, during the prediction of the external set of known anti-tubercular compounds/drugs, it was realized that each of these models had some limitations. The ABDT model correctly predicted 22 molecules as actives, while both the RF and k-NN models predicted 18 molecules correctly as actives; a number of molecules were predicted as actives by two of these models, while the third model predicted these compounds as inactives. Therefore, we concluded that while deciding the anti-tubercular potential of a new molecule, one should rely on the use of consensus predictions using these three models; it may lessen the attrition rate during the in vitro validation. We believe that this study may assist the wider anti-tuberculosis research community by providing a platform for predicting small molecules with subsequent validation for drug discovery and development.


Subject(s)
Machine Learning , Support Vector Machine , Algorithms , Antitubercular Agents/pharmacology , Bayes Theorem , Consensus
11.
J Biomol Struct Dyn ; 40(20): 10181-10190, 2022.
Article in English | MEDLINE | ID: mdl-34157950

ABSTRACT

The orphan class A G-protein coupled receptor 3 (GPR3) is highly expressed in brain and linked with various neuronal functions, and therefore, expected to play a vital role in the progression of Alzheimer's disease. In view of the lack of its experimental structure, we describe herein the three-dimensional structure and conformational dynamics of GPR3 complexed with the inverse agonist AF64394. The GPR3 model was predicted using the Iterative Threading ASSEmbly Refinement (I-TASSER) method. The Induced Fit Docking predicted two unique poses, Pose 1 and Pose 2, for AF64394, and then, molecular dynamics (MD) simulations followed by binding free-energy calculation revealed the Pose 1 as a very stable pose with the least fluctuation during the MD simulation while the Pose 2 underwent a significant fluctuation. The [1,2,4]triazolo[1,5-a]pyrimidine core was engaged in multiple hydrogen bonds (H-bonds), such as a water-mediated H-bond between the triazole nitrogen and T31, two direct H-bonds between the protonated triazole-ring nitrogen and V186 and T279, a direct H-bond between the secondary amine and V187. The phenyl substituent of AF64394 exhibited aromatic π-π stacking interactions with F97, F101, W43 and Y280. AF64394 showed a direct interaction with E28 and polar interactions with H96, T31 and T279. Throughout the MD simulation, the toggle switch residues, F120 and W260, remained in close contact, indicating that the GPR3 conformation represented an inactive state. The 4-(3-chloro-5-isopropoxyphenethyl) group resided near to the toggle switch residues. The insights gained here are expected to be useful in the structure-based design of new ligands targeting GPR3 modulation. Communicated by Ramaswamy H. Sarma.


Subject(s)
Drug Inverse Agonism , Receptors, G-Protein-Coupled , Humans , Ligands , Molecular Dynamics Simulation , Nitrogen , Receptors, G-Protein-Coupled/agonists , Receptors, G-Protein-Coupled/chemistry , Triazoles
12.
Chem Biol Drug Des ; 99(3): 496-503, 2022 03.
Article in English | MEDLINE | ID: mdl-34951520

ABSTRACT

Inhibition of extracellular secreted enzyme autotaxin (ATX) represents an attractive strategy for the development of new therapeutics to treat various diseases and a few inhibitors entered in clinical trials. We herein describe structure-based design, synthesis, and biological investigations revealing a potent and orally bioavailable ATX inhibitor 1. During the molecular docking and scoring studies within the ATX enzyme (PDB-ID: 4ZGA), the S-enantiomer (Gscore = -13.168 kcal/mol) of the bound ligand PAT-494 scored better than its R-enantiomer (Gscore = -9.562 kcal/mol) which corroborated with the reported observation and analysis of the results suggested the scope of manipulation of the hydantoin substructure in PAT-494. Accordingly, the docking-based screening of a focused library of 10 compounds resulted in compound 1 as a better candidate for pharmacological studies. Compound 1 was synthesized from L-tryptophan and evaluated against ATX enzymatic activities with an IC50 of 7.6 and 24.6 nM in biochemical and functional assays, respectively. Further, ADME-PK studies divulged compound 1 as non-cytotoxic (19.02% cell growth inhibition at 20 µM in human embryonic kidney cells), metabolically stable against human liver microsomes (CLint  = 15.6 µl/min/mg; T1/2  = 113.2 min) with solubility of 4.82 µM and orally bioavailable, demonstrating its potential to be used for in vivo experiments.


Subject(s)
Drug Design , Enzyme Inhibitors/chemistry , Indoles/chemistry , Phosphoric Diester Hydrolases/chemistry , Administration, Oral , Animals , Binding Sites , Drug Stability , Enzyme Inhibitors/metabolism , Enzyme Inhibitors/pharmacokinetics , Half-Life , Humans , Imidazoles/chemistry , Indoles/metabolism , Indoles/pharmacokinetics , Microsomes, Liver/metabolism , Molecular Docking Simulation , Phosphoric Diester Hydrolases/metabolism , Pyridines/chemistry , Rats , Rats, Sprague-Dawley , Stereoisomerism
13.
Med Biol Eng Comput ; 59(11-12): 2397-2408, 2021 Nov.
Article in English | MEDLINE | ID: mdl-34632545

ABSTRACT

The ubiquitous antimicrobial peptides (AMPs), with a broad range of antimicrobial activities, represent a great promise for combating the multi-drug resistant infections. In this study, using a large and diverse set of AMPs (2638) and non-AMPs (3700), we have explored a variety of machine learning classifiers to build in silico models for AMP prediction, including Random Forest (RF), k-Nearest Neighbors (k-NN), Support Vector Machine (SVM), Decision Tree (DT), Naive Bayes (NB), Quadratic Discriminant Analysis (QDA), and ensemble learning. Among the various models generated, the RF classifier-based model top-performed in both the internal [Accuracy: 91.40%, Precision: 89.37%, Sensitivity: 90.05%, and Specificity: 92.36%] and external validations [Accuracy: 89.43%, Precision: 88.92%, Sensitivity: 85.21%, and Specificity: 92.43%]. In addition, the RF classifier-based model correctly predicted the known AMPs and non-AMPs; those kept aside as an additional external validation set. The performance assessment revealed three features viz. ChargeD2001, PAAC12 (pseudo amino acid composition), and polarity T13 that are likely to play vital roles in the antimicrobial activity of AMPs. The developed RF-based classification model may further be useful in the design and prediction of the novel potential AMPs.


Subject(s)
Machine Learning , Support Vector Machine , Bayes Theorem , Discriminant Analysis , Pore Forming Cytotoxic Proteins
14.
Chemosphere ; 283: 131114, 2021 Nov.
Article in English | MEDLINE | ID: mdl-34147974

ABSTRACT

The present study has investigated p-nitrophenol (PNP) degradation by hybrid advanced oxidation process (AOP) of hydrodynamic cavitation with heterogenous Fe3O4 nanoparticles. 78.8 ± 1.2% of PNP degradation was obtained at optimum operational conditions: inlet pressure = 8 atm, pH = 3, initial concentration of PNP = 20 mg L-1, Fe3O4:H2O2 = 1:100. PNP degradation profiles were analyzed using a kinetic model based on the reaction network. The closest match between the simulated and experimental degradation profiles was obtained for the initial concertation of [H2O2] = 0.6 M, which was far higher than concentration of externally added H2O2. This was attributed to in-situ generation of H2O2 through transient cavitation. Intense shear and turbulence generated in cavitating flow caused surface leaching of Fe3O4 particles that released Fe2+/Fe3+ ions. The synergy in the hybrid AOP was in-situ Fenton reactions between leached Fe2+/Fe3+ ions and H2O2 present in the reaction mixture. The mechanism in •OH mediated oxidative degradation of PNP was further explored with Density Functional Theory (DFT) simulations. Both •OH addition on benzene ring and H-abstraction reactions were simulated to identify the possible pathways for the degradation. On the basis of activation free energy analysis, degradation pathways initiating with both •OH addition and H abstraction were determined to be feasible. The ortho-C of benzene ring was the most favourable site for •OH addition, while H atom of phenolic hydroxyl group was more susceptible (or more reactive) for H-atom abstraction route.


Subject(s)
Hydrodynamics , Hydrogen Peroxide , Iron , Nitrophenols , Oxidation-Reduction
15.
Ultrason Sonochem ; 67: 105127, 2020 Oct.
Article in English | MEDLINE | ID: mdl-32334378

ABSTRACT

Sonication is known to enhance crystallization of lactose from aqueous solutions. This study has attempted to reveal the mechanistic features of antisolvent crystallization of lactose monohydrate from aqueous solutions. Experiments were conducted in three protocols, viz. mechanical stirring, mechanical stirring with sonication and sonication at elevated static pressure. Mechanical stirring provided macroconvection while sonication induced microconvection in the system. Other experimental parameters were initial lactose concentration and rate of antisolvent (ethanol) addition. Kinetic parameters of crystallization were coupled with simulations of bubble dynamics. The growth rate of crystals, rate of nucleation, average size of crystal crop and total lactose yield in different protocols were related to nature of convection in the medium. Macroconvection assisted nucleation but could not give high growth rate. Microconvection comprised of microstreaming due to ultrasound and acoustic (or shock) waves due to transient cavitation. Sonication at atmospheric static pressure enhanced growth rate but reduced nucleation. However, with elimination of cavitation at elevated static pressure, sonication enhanced both nucleation and growth rate resulting in almost complete lactose recovery.

16.
mSphere ; 5(1)2020 01 08.
Article in English | MEDLINE | ID: mdl-31915228

ABSTRACT

The cell wall-targeting echinocandin antifungals, although potent and well tolerated, are inadequate in treating fungal infections due to their narrow spectrum of activity and their propensity to induce pathogen resistance. A promising strategy to overcome these drawbacks is to combine echinocandins with a molecule that improves their activity and also disrupts drug adaptation pathways. In this study, we show that puupehenone (PUUP), a marine-sponge-derived sesquiterpene quinone, potentiates the echinocandin drug caspofungin (CAS) in CAS-resistant fungal pathogens. We have conducted RNA sequencing (RNA-seq) analysis, followed by genetic and molecular studies, to elucidate PUUP's CAS-potentiating mechanism. We found that the combination of CAS and PUUP blocked the induction of CAS-responding genes required for the adaptation to cell wall stress through the cell wall integrity (CWI) pathway. Further analysis showed that PUUP inhibited the activation of Slt2 (Mpk1), the terminal mitogen-activated protein (MAP) kinase in this pathway. We also found that PUUP induced heat shock response genes and inhibited the activity of heat shock protein 90 (Hsp90). Molecular docking studies predicted that PUUP occupies a binding site on Hsp90 required for the interaction between Hsp90 and its cochaperone Cdc37. Thus, we show that PUUP potentiates CAS activity by a previously undescribed mechanism which involves a disruption of Hsp90 activity and the CWI pathway. Given the requirement of the Hsp90-Cdc37 complex in Slt2 activation, we suggest that inhibitors of this complex would disrupt the CWI pathway and synergize with echinocandins. Therefore, the identification of PUUP's CAS-potentiating mechanism has important implications in the development of new antifungal combination therapies.IMPORTANCE Fungal infections cause more fatalities worldwide each year than malaria or tuberculosis. Currently available antifungal drugs have various limitations, including host toxicity, narrow spectrum of activity, and pathogen resistance. Combining these drugs with small molecules that can overcome these limitations is a useful strategy for extending their clinical use. We have investigated the molecular mechanism by which a marine-derived compound potentiates the activity of the antifungal echinocandin caspofungin. Our findings revealed a mechanism, different from previously reported caspofungin potentiators, in which potentiation is achieved by the disruption of Hsp90 activity and signaling through the cell wall integrity pathway, processes that play important roles in the adaptation to caspofungin in fungal pathogens. Given the importance of stress adaptation in the development of echinocandin resistance, this work will serve as a starting point in the development of new combination therapies that will likely be more effective and less prone to pathogen resistance.


Subject(s)
Caspofungin/pharmacology , Cell Wall/drug effects , Drug Resistance, Fungal/genetics , HSP90 Heat-Shock Proteins/antagonists & inhibitors , Saccharomyces cerevisiae/genetics , Sesquiterpenes/pharmacology , Xanthones/pharmacology , Antifungal Agents/pharmacology , Cell Wall/metabolism , Fungal Proteins/genetics , Molecular Docking Simulation , Saccharomyces cerevisiae/drug effects , Sequence Analysis, RNA
17.
J Biomol Struct Dyn ; 38(1): 32-47, 2020 01.
Article in English | MEDLINE | ID: mdl-30652534

ABSTRACT

Selective activation of the cannabinoid receptor subtype 2 (CB2) shows promise for treating pain, inflammation, multiple sclerosis, cancer, ischemic/reperfusion injury and osteoporosis. Target selectivity and off-target side effects are two major limiting factors for orthosteric ligands, and therefore, the search for allosteric modulators (AMs) is a widely used drug discovery approach. To date, only a limited number of negative CB2 AMs have been identified, possessing only micromolar activity at best, and the CB2 receptor's allosteric site(s) are not well characterized. Herein, we used computational approaches including receptor modeling, site mapping, docking, molecular dynamics (MD) simulations and binding free energy calculations to predict, characterize and validate allosteric sites within the complex of the CB2 receptor with bound orthosteric agonist CP55,940. After docking of known negative CB2 allosteric modulators (NAMs), dihydro-gambogic acid (DHGA) and trans-ß-caryophyllene (TBC) (note that TBC also shows agonist activity), at the predicted allosteric sites, the best total complex with CB2, CP55,940 and NAM was embedded into a hydrated lipid bilayer and subjected to a 200 ns MD simulation. The presence of an AM affected the CB2-CP55,940 complex, altering the relative positioning of the toggle switch residues and promoting a strong π-π interaction between Phe1173.36 and Trp2586.48. Binding of either TBC or DHGA to a putative allosteric pocket directly adjacent to the orthosteric ligand reduced the binding free energy of CP55,940, which is consistent with the expected effect of a negative AM. The identified allosteric sites present immense scope for the discovery of novel classes of CB2 AMs.


Subject(s)
Allosteric Regulation , Allosteric Site , Cannabinoid Receptor Agonists/chemistry , Molecular Docking Simulation , Molecular Dynamics Simulation , Receptor, Cannabinoid, CB2/chemistry , Amino Acid Sequence , Binding Sites , Cannabinoid Receptor Agonists/pharmacology , Hydrogen Bonding , Ligands , Molecular Conformation , Molecular Structure , Protein Binding , Protein Interaction Domains and Motifs , Receptor, Cannabinoid, CB2/agonists , Structure-Activity Relationship
18.
J Biomol Struct Dyn ; 38(10): 3074-3086, 2020 Jul.
Article in English | MEDLINE | ID: mdl-31378153

ABSTRACT

Osteoarthritis (OA) is the most common form of arthritis with no available disease-modifying treatments, and is a major cause of disability. Matrix metalloproteinase 13 (MMP-13) is vital for OA progression and thus, inhibition of MMP-13 is an effective strategy to treat OA. Since the past few decades, drug repurposing has gained substantial popularity worldwide as a time- and cost-effective approach to find new indications for the existing drugs. Therefore, more than 40 X-ray co-crystal structures of the human MMP-13 with bound inhibitors are investigated to gain the structural insights such as conserved direct interactions with binding site residues, namely Ala-238, Thr-245 and Thr-247. Afterwards, enrichment study using active and decoy set of ligands revealed three MMP-13 structures (PDB-IDs: 1XUC, 3WV1 and 5BPA) with optimal enrichment performance. Docking-based screening of existing drugs against the three crystal structures followed by binding free-energy calculation suggested drugs namely eltrombopag, cilostazol and domperidone as potential MMP-13 inhibitors that need further experimental validation. These insights may serve as a potential starting point of further experimental validation and structure-based drug design/repurposing of MMP-13 inhibitors for the treatment of OA. Abbreviations2Dtwo-dimensional3Dthree-dimensionalFDAFood and Drug AdministrationMM-GBSAMolecular Mechanics Generalized Born Surface AreaMMPsmatrix metalloproteinasesMMP-13matrix metalloproteinase 13NMRnuclear magnetic resonanceOAosteoarthritisPDBProtein Data BankPDB-IDProtein Data Bank IDPLIPprotein-ligand interaction profilerROCreceiver operating characteristic,RMSDroot mean square deviationCommunicated by Ramaswamy H. Sarma.


Subject(s)
Matrix Metalloproteinase Inhibitors , Osteoarthritis , Humans , Matrix Metalloproteinase 13 , Matrix Metalloproteinase Inhibitors/pharmacology , Molecular Docking Simulation , Osteoarthritis/drug therapy , Prospective Studies
19.
Expert Opin Drug Discov ; 15(2): 231-241, 2020 02.
Article in English | MEDLINE | ID: mdl-31774006

ABSTRACT

Introduction: Tuberculosis (TB) is a leading infectious disease worldwide whose chemotherapy is challenged by the continued rise of drug resistance. This epidemic urges the need to discover anti-TB drugs with novel modes of action.Areas covered: The mycobacterial electron transport chain (ETC) pathway represents a hub of anti-TB drug targets. Herein, the authors highlight the various targets within the mycobacterial ETC and highlight some of the promising ETC-targeted drugs and clinical candidates that have been discovered or repurposed. Furthermore, recent breakthroughs in the availability of X-ray and/or cryo-EM structures of some targets are discussed, and various opportunities of exploiting these structures for the discovery of new anti-TB drugs are emphasized.Expert opinion: The drug discovery efforts targeting the ETC pathway have led to the FDA approval of bedaquiline, a FOF1-ATP synthase inhibitor, and the discovery of Q203, a clinical candidate drug targeting the mycobacterial cytochrome bcc-aa3 supercomplex. Moreover, clofazimine, a proposed prodrug competing with menaquinone for its reduction by mycobacterial NADH dehydrogenase 2, has been repurposed for TB treatment. Recently available structures of the mycobacterial ATP synthase C9 rotary ring and the cytochrome bcc-aa3 supercomplex represent further opportunities for the structure-based drug design (SBDD) of the next-generation of inhibitors against Mycobacterium tuberculosis.


Subject(s)
Antitubercular Agents/pharmacology , Drug Discovery , Tuberculosis, Multidrug-Resistant/drug therapy , Antitubercular Agents/chemistry , Drug Design , Electron Transport/drug effects , Humans , Mycobacterium tuberculosis/drug effects , Tuberculosis, Multidrug-Resistant/microbiology
20.
Ultrason Sonochem ; 62: 104890, 2020 Apr.
Article in English | MEDLINE | ID: mdl-31796330

ABSTRACT

This study has addressed the biodegradation of polycyclic aromatic hydrocarbon, phenanthrene using Candida tropicalis. Optimization using central composite statistical design yielded optimum experimental parameters as: pH = 6.2, temperature = 33.4 °C, mechanical shaking = 190 rpm and % inoculum = 9.26% v/v. Sonication of biodegradation mixture at 33 kHz and 10% duty cycle in log phase (12 h per day for 4 days) resulted in a 25% enhancement in phenanthrene removal. Profiles of specific growth rate (µ) and specific degradation rate (q) versus initial substrate concentration were fitted to Haldane substrate inhibition model. Both µ and q showed maxima for initial concentration of 100 mg L-1. Kinetic analysis of degradation profiles showed higher biomass yield coefficient and smaller decay coefficient in presence of sonication. Expression of total intracellular proteins in control and test experiments were analyzed using SDS-PAGE. This analysis revealed overexpression of enzyme catechol 2,3-dioxygenase (in meta route metabolism) during sonication which is involved in ring cleavage of phenanthrene. Evaluation of cell viability after sonication by flow cytometry analysis revealed > 80% live cells. These effects are attributed to enhanced cellular transport induced by intense microturbulence generated by sonication.


Subject(s)
Biodegradation, Environmental , Phenanthrenes/metabolism , Polycyclic Aromatic Hydrocarbons/metabolism , Sonication , Biological Oxygen Demand Analysis , Candida tropicalis/metabolism , Catechol 2,3-Dioxygenase/metabolism , Electrophoresis, Polyacrylamide Gel , Fungal Proteins/metabolism , Spectroscopy, Fourier Transform Infrared
SELECTION OF CITATIONS
SEARCH DETAIL
...